The use of adjuvant pertuzumab in HER2-positive early-stage breast cancer has recently been approved by the EMA on the basis of data from the APHINITY trial. Accordingly, we have produced this opinion article with the aim of putting the study data in perspective against other add-on therapeutic strategies, to clarify methodological or statistical doubts about the study, and to define the population of high-risk patients with hormone receptor-negative breast cancer that we agree, in general, should be treated. With this approval, physicians must be well prepared to place the APHINITY study data in context. It is now up to each country to ratify the EMA-approved indications and to agree on reimbursement, and doctors must optimize their use based on knowledge and discussion with patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.101944DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
study data
8
contextualizing pertuzumab
4
pertuzumab approval
4
approval treatment
4
treatment her2-positive
4
her2-positive breast
4
cancer patients
4
patients adjuvant
4
adjuvant pertuzumab
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!